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Abstract
Intracranial mesenchymal tumors with FET-CREB fusions are a recently 
described group of neoplasms in children and young adults characterized by 
fusion of a FET family gene (usually EWSR1, but rarely FUS) to a CREB fam-
ily transcription factor (ATF1, CREB1, or CREM), and have been variously 
termed intracranial angiomatoid fibrous histiocytoma or intracranial myxoid 
mesenchymal tumor. The clinical outcomes, histologic features, and genomic 
landscape are not well defined. Here, we studied 20 patients with intracranial 
mesenchymal tumors proven to harbor FET-CREB fusion by next-generation 
sequencing (NGS). The 16 female and four male patients had a median age of 
14  years (range 4–70). Tumors were uniformly extra-axial or intraventricular 
and located at the cerebral convexities (n = 7), falx (2), lateral ventricles (4), ten-
torium (2), cerebellopontine angle (4), and spinal cord (1). NGS demonstrated 
that eight tumors harbored EWSR1-ATF1 fusion, seven had EWSR1-CREB1, 
four had EWSR1-CREM, and one had FUS-CREM. Tumors were uniformly 
well circumscribed and typically contrast enhancing with solid and cystic 
growth. Tumors with EWSR1-CREB1 fusions more often featured stellate/
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1 |  INTRODUCTION
Intracranial mesenchymal tumors with FET-CREB fu-
sions comprise a rare group of neoplasms of the central 
nervous system (CNS) that have been variably described 
as intracranial angiomatoid fibrous histiocytoma (AFH), 
and more recently as intracranial myxoid mesenchymal 
tumor (IMMT) (1–4). Despite their disparate names, in-
tracranial AFH and IMMT are both molecularly defined 
by in-frame gene fusions of the FET family of RNA-
binding proteins (EWSR1 or FUS) to the CREB (cyclic 
AMP response element-binding protein) family of tran-
scription factors, which includes ATF1, CREB1, and 
CREM. Notably, identical FET-CREB fusions are recur-
rently found in extracranial AFH, clear cell sarcoma of 
soft tissue, clear cell sarcoma of the gastrointestinal tract, 
primary pulmonary myxoid sarcoma, hyalinizing clear 
cell carcinoma of the salivary gland, and a subset of ma-
lignant mesotheliomas lacking BAP1 and NF2 alterations 
(5–15). However, the exact relation of these intracranial 
mesenchymal tumors with FET-CREB fusions to extra-
cranial AFH and other FET-CREB fusion-driven neo-
plasms remains unknown.
AFH has been characterized in the soft tissue as an 
uncommon neoplasm of intermediate malignancy com-
prising 0.3% of all soft tissue tumors, most frequently 
occurring in the subcutaneous tissue of the extremities 
in children and young adults, but occasionally can be lo-
cated within the viscera or retroperitoneum (5,14,16,17). 
They display a characteristic histomorphology with four 
defining characteristics, although not all are required for 
diagnosis: solid nodules of epithelioid or spindled cells 
with a syncytial growth pattern, pseudoangiomatous 
spaces, a fibrous pseudocapsule, and robust pericapsu-
lar lymphoplasmacytic inflammatory infiltrates with 
germinal center formation. AFH is well-described to dis-
play a spectrum of variant histomorphologies, such as 
prominent myxoid stroma prompting some to describe 
a myxoid variant of AFH (15,18–21). In one series, three 
AFH with myxoid features occurring in the extremities 
(two cases) or lung (one case) harbored EWSR1-CREM 
fusions (15).
Several intracranial mesenchymal tumors histolog-
ically resembling AFH or the myxoid variant of AFH 
and harboring FET-CREB fusions have now been re-
ported (1–4,22–33). Kao et al first reported in 2017 four 
children and young adults with intracranial myxoid 
mesenchymal neoplasms with EWSR1-CREB1, EWSR1-
CREM, or EWSR1-ATF1 fusions (3). Shortly thereafter, 
Bale et al reported three additional pediatric patients 
with tumors composed of similar histologic features 
and EWSR1-CREB1 or EWSR1-CREM fusions (1). The 
authors postulated that these tumors may represent a 
myxoid variant of AFH occurring intracranially, or 
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spindle cell morphology, mucin-rich stroma, and hemangioma-like vasculature 
compared to tumors with EWSR1-ATF1 fusions that most often featured sheets 
of epithelioid cells with mucin-poor collagenous stroma. These tumors dem-
onstrated polyphenotypic immunoprofiles with frequent positivity for desmin, 
EMA, CD99, MUC4, and synaptophysin, but absence of SSTR2A, myogenin, 
and HMB45 expression. There was a propensity for local recurrence with a 
median progression-free survival of 12 months and a median overall survival 
of greater than 60 months, with three patients succumbing to disease (all with 
EWSR1-ATF1 fusions). In combination with prior case series, this study pro-
vides further insight into intracranial mesenchymal tumors with FET-CREB 
fusion, which represent a distinct group of CNS tumors encompassing both in-
tracranial myxoid mesenchymal tumor and angiomatoid fibrous histiocytoma-
like neoplasms.
K E Y W O R D S
angiomatoid fibrous histiocytoma (AFH), brain tumor, CREB, EWSR1, intracranial myxoid 
mesenchymal tumor, molecular neuropathology, sarcoma
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alternatively a novel intracranial tumor entity (IMMT). 
The reported cases of IMMT had mucin-rich stroma, 
often lacked some of the characteristic histologic fea-
tures of AFH, and were enriched for CREM fusions that 
are rare in AFH of extracranial soft tissue. Despite some 
morphologic similarities, they also have a spectrum of 
morphologic appearances that partially overlap with 
those of conventional AFH, including pseudo-encap-
sulation, nodular proliferations of epithelioid cells, and 
prominent subcapsular lymphoplasmacytic aggregates 
with hemosiderin deposition (1,3). The immunoprofiles 
of both intracranial AFH-like tumors and IMMT are 
similar to conventional AFH of extracranial soft tissue 
(1–3). Tumor cells are consistently positive for desmin (at 
least focally), but are negative for skeletal muscle mark-
ers including myogenin and MyoD1, as well as smooth 
muscle markers including smooth muscle actin, caldes-
mon, and calponin. There is also positivity for CD99 and 
EMA in the majority of tumors, while they are consis-
tently negative for melanocytic markers (S100, HMB45) 
and glial markers (GFAP and OLIG2). CD68 and CD163 
have been positive in both neoplastic cells and tumor-as-
sociated macrophages. However, the clinical features, 
patient outcomes, and optimal treatment strategies for 
these tumors remain largely undefined.
Therefore, to further investigate the clinical, ra-
diologic, and pathologic features of intracranial mes-
enchymal tumors with FET-CREB fusions, we have 
comprehensively studied a cohort of 20 patients and re-
viewed the previously reported cases of these tumors in 
the published literature.
2 |  M ATERI A LS A N D M ETHODS
2.1 | Study population and tumor specimens
The study cohort consisted of 20 patients who underwent 
surgical resection of a primary intracranial neoplasm 
that was identified to harbor a gene fusion of EWSR1 
or the related FUS together with a CREB family mem-
ber (ATF1, CREB1, or CREM). Pathologic review of all 
tumor specimens was performed by a group of expert 
neuropathologists (E.A.S., A.P., and D.A.S.).
2.2 | Immunohistochemistry
Immunohistochemistry was performed on whole forma-
lin-fixed, paraffin-embedded tissue sections using the 
following antibodies: desmin (Cell Marque, clone D33, 
undiluted, ER1 antigen retrieval), epithelial membrane 
antigen (EMA, Leica, clone GP1.4, undiluted, ER1 an-
tigen retrieval), CD99 (Signet, clone CD99, 1:400 dilu-
tion, ER1 antigen retrieval), S100 (DAKO, polyclonal, 
1:2,000 dilution, no antigen retrieval), MUC4 (Millipore, 
clone 8G7, 1:500 dilution, ER1 antigen retrieval), 
pan-neurotrophic receptor tyrosine kinase protein fam-
ily (pan-NTRK, Abcam, clone EPR-17341, 1:100 dilu-
tion, ER2 antigen retrieval), somatostatin receptor 2A 
(SSTR2A, Abcam, clone UMB1, 1:2,000 dilution, ER2 
antigen retrieval), OLIG2 (Immuno Bio Labs, polyclonal, 
1:200 dilution, ER1 antigen retrieval), glial fibrillary 
acidic protein (GFAP, DAKO, polyclonal, 1:3,000 dilu-
tion, no antigen retrieval), synaptophysin (Cell Marque, 
polyclonal, 1:100 dilution, ER2 antigen retrieval), CD68 
(Leica, clone 514H12, undiluted, ER2 antigen retrieval), 
cytokeratin AE1/AE3 (Dako, clone AE1/AE3, 1:100 di-
lution, ER1 antigen retrieval), cytokeratin CAM5.2 
(Becton Dickinson, clone CAM5.2, 1:100 dilution, ER1 
antigen retrieval), HMB45 (Dako, clone HMB45, undi-
luted, CC1 antigen retrieval), myogenin (Cell Marque, 
clone F5D, undiluted, CC1 antigen retrieval), and Ki-67 
(Dako, clone Mib1, 1:50 dilution, ER2 antigen retrieval). 
Immunostaining for desmin, EMA, CD99, S100, MUC4, 
pan-NTRK, SSTR2A, OLIG2, GFAP, synaptophysin, 
CD68, cytokeratin AE1/AE3, cytokeratin CAM5.2, and 
Ki-67 was performed in a Leica Bond-Max automated 
stainer. Immunostaining for HMB45 and myogenin was 
performed in a Ventana BenchMark Ultra-automated 
stainer. Diaminobenzidine was used as the chromogen, 
followed by hematoxylin counterstain.
2.3 | Targeted next-generation DNA 
sequencing analysis
Tumor tissue was selectively scraped from unstained 
slides or punched from formalin-fixed, paraffin- 
embedded (FFPE) blocks using 2.0  mm disposable bi-
opsy punches (Integra Miltex Instruments) to enrich for 
as high tumor content as possible. Genomic DNA was 
extracted from this macrodissected tumor tissue using 
the QIAamp DNA FFPE Tissue Kit (Qiagen). Tumor tis-
sue from both the initial surgical resection and a subse-
quent recurrence was sequenced for one patient (ATF1 
#2). Capture-based next-generation DNA sequencing 
was performed using an assay that targets all coding 
exons of 479 cancer-related genes, select introns and up-
stream regulatory regions of 47 genes to enable detection 
of structural variants including gene fusions, and DNA 
segments at regular intervals along each chromosome to 
enable genome-wide copy number and zygosity analysis, 
with a total sequencing footprint of 2.8 Mb (UCSF500 
Cancer Panel) (34). Multiplex library preparation was 
performed using the KAPA Hyper Prep Kit (Roche) 
according to the manufacturer's specifications. Hybrid 
capture of pooled libraries was performed using a cus-
tom oligonucleotide library (NimbleGen SeqCap EZ 
Choice). Captured libraries were sequenced as paired-
end 100 bp reads on an Illumina HiSeq 2500 instrument. 
Sequence reads were mapped to the reference human ge-
nome build GRCh37 (hg19) using the Burrows–Wheeler 
aligner (BWA). Recalibration and deduplication of reads 
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was performed using the Genome Analysis Toolkit 
(GATK). Coverage and sequencing statistics were de-
termined using Picard CalculateHsMetrics and Picard 
CollectInsertSizeMetrics. Single nucleotide variant and 
small insertion/deletion mutation calling was performed 
with FreeBayes, Unified Genotyper, and Pindel. Large 
insertion/deletion and structural alteration calling was 
performed with Delly. Variant annotation was per-
formed with ANNOVAR. Single nucleotide variants, 
insertions/deletions, and structural variants were visu-
alized and verified using Integrative Genome Viewer. 
Genome-wide copy number and zygosity analysis was 
F I G U R E  1  Radiologic features of intracranial mesenchymal tumors with FET-CREB fusion. These tumors were typically contrast 
enhancing and often demonstrated both solid and cystic components with extensive peritumoral edema
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performed by CNVkit and visualized using Nexus Copy 
Number (Biodiscovery).
2.4 | Reverse-transcription PCR
Total RNA was extracted from formalin-fixed paraf-
fin-embedded tissue using the RNeasy FFPE Isolation 
Kit (Qiagen). Reverse transcriptase-polymerase chain 
reaction (RT-PCR) was performed using SuperScript 
III One-Step RT-PCR System (Life Technologies) and 
the following primers: FUS, 5′-TGGACAGCAGAACC 
AGTACA-3′ and CREM, 5′-CAGTAGGAGCTCGGA 
TCTGG-3′. RT-PCR products were resolved by agarose 
gel by electrophoresis and Sanger sequenced using 
BigDye terminator chemistry (Applied Biosystems) fol-
lowing standard techniques.
2.5 | Kaplan–Meier survival plots and 
statistical analyses
Clinical outcomes were studied by Kaplan–Meier analy-
sis using GraphPad Prism. The Kaplan–Meier survival 
analysis stratified by extent of resection includes only 
the 17 patients from this cohort with known extent of 
resection. Additional Kaplan–Meier survival analyses 
include the 20 patients from this cohort combined with 
the 18 prior cases of intracranial mesenchymal tumors 
with FET-CREB fusions reported in the literature. 
p values were calculated by Log-rank (Mantel-Cox) test. 
Statistical comparison of histologic features was per-
formed by Mann–Whitney unpaired two-tailed t test 
using GraphPad Prism.
3 |  RESU LTS
3.1 | Clinical features
The 16 female and four male patients had a median age 
of 14 years (range 4–70 years) (Table 1). Two of the pa-
tients had a known history of prior neoplasia. Patient 
CREB1 #3 had a history of pre-B acute lymphoblastic 
leukemia at 10 years of age (7 years prior to the diagno-
sis of intracranial mesenchymal tumor with EWSR1-
CREB1 fusion), for which he received treatment with 
prednisone and methotrexate but no radiation therapy. 
Patient CREB1 #7 had a history of high-risk adrenal 
neuroblastoma for which he received local radiation 
F I G U R E  2  Chromosomal copy number analysis demonstrates that EWSR1-ATF1 and EWSR1-CREB1 fusions typically result from 
balanced translocations, whereas EWSR1-CREM fusions typically result from unbalanced translocations
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treatment and systemic chemotherapy, but the poste-
rior fossa where the intracranial mesenchymal tumor 
with EWSR1-CREB1 fusion developed 5  years later 
was outside the radiation treatment field. None of the 
patients had a known tumor predisposition syndrome 
or other known predisposing factors to neoplasia, and 
none of the patients had evidence of extracranial neo-
plasms at time of diagnosis to suggest the possibility of 
metastatic disease. Presenting symptoms were variable 
and most frequently included severe headaches or nau-
sea, and also occasionally seizures, tinnitus, or diplo-
pia (Table S1).
3.2 | Radiologic features
Tumors were exclusively extra-axial in the meninges with 
compression of the subjacent brain parenchyma or in-
traventricular, with locations at the cerebral convexities 
(n = 7), falx (2), lateral ventricles (4), tentorium (2), cer-
ebellopontine angle (4), and spinal cord (1). Radiologic 
characteristics include circumscribed and lobulated 
growth, often with both solid and cystic components, 
avid enhancement after contrast administration, intra-
tumoral blood products, and substantial peritumoral 
edema (Figure 1). Some tumors showed a dural tail or 
F I G U R E  3  Histologic features of intracranial mesenchymal tumors with FET-CREB fusion. Those tumors with EWSR1-ATF1 fusion were 
most often composed of sheets of epithelioid to rhabdoid cells in a mucin-poor collagenous stroma. Those tumors with EWSR1-CREB1 or 
EWSR1-CREM fusions were most often composed of cords and clusters of stellate to spindle cells in a mucin-rich stroma
2 of 21 |   SLOAN et AL.
bony involvement of the overlying skull mimicking men-
ingioma. One patient (ATF1 #7) demonstrated a mass 
in the cerebellopontine (CP) angle with diffuse leptome-
ningeal dissemination along the spinal cord, whereas all 
other patients had localized disease without dissemina-
tion at time of presentation.
3.3 | Genomic features
Next-generation sequencing (NGS) revealed that eight 
tumors harbored EWSR1-ATF1 fusion, seven had 
EWSR1-CREB1 fusion, four had EWSR1-CREM fu-
sion, and one had FUS-CREM fusion. The fusions 
F I G U R E  4  Specific histologic features recurrently observed in intracranial mesenchymal tumors with FET-CREB fusion. Example 
illustrations are shown of the characteristic histologic features recurrently observed across all fusion types (e.g., collagenous stroma, 
lymphoplasmacytic cuffing) and those enriched in specific fusion types (e.g., epithelioid/rhabdoid cell morphology with EWSR1-ATF1 fusion; 
mucin-rich stroma, stellate/spindle cell morphology, and hemangioma-like vasculature with EWSR1-CREB1 fusion)
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linked the 5′ coding exons of either EWSR1 or FUS to 
the 3′ coding exons of ATF1, CREB1, or CREM. The 
predicted fusion transcript most commonly linked exons 
1–8 of EWSR1 to exons 5–7 of ATF1, 7–9 of CREB1, and 
7–8 of CREM (Table S2). No likely pathogenic single nu-
cleotide variants or indels were identified in any of the 20 
tumors. Specifically, no TERT promoter hotspots muta-
tions were present. No mutations or other alterations in 
genes known to be recurrently altered in meningiomas 
were identified (e.g., NF2, TRAF7, KLF4, AKT1, SMO, 
PIK3CA, SMARCB1, BAP1, and YAP1) (35,36). All tu-
mors lacked STAT6 rearrangements that are defining of 
solitary fibrous tumor/hemangiopericytoma, and lacked 
PAX3/7-FOXO1 fusions that characterize most alveolar 
rhabdomyosarcomas (37,38).
Many of the tumors demonstrated a diploid genome 
(n = 10), whereas the remaining demonstrated a paucity 
of chromosomal gains or losses (Table S3). All of the 
F I G U R E  4 .  (Continued) 
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tumors with either EWSR1-ATF1 or EWSR1-CREB1 
fusion appear to have resulted from balanced translo-
cations with an absence of copy number breakpoints at 
chromosomes 22q12, 12q13, or 2q33 where these three 
genes are located (Figure 2). In contrast, all five tumors 
with either EWSR1-CREM or FUS-CREM fusion ap-
pear to have resulted from unbalanced translocations 
(Figure 2). Recurrent loss of distal 10p with a break-
point occurring at the CREM locus at 10p11 was seen 
in all five tumors, accompanied by either loss of distal 
22q with a breakpoint occurring at the EWSR1 locus at 
22q12, or gain of distal 16p with a breakpoint at the FUS 
locus at 16p11.
3.4 | Histologic features
The intracranial mesenchymal tumors with FET-CREB 
fusion in this series demonstrated a wide morphologic 
spectrum with several recurrent histologic features, some 
of which were observed among tumors with all fusion 
types and some of which were enriched in tumors with 
specific fusion types (Figures 3 and 4, and Table 2). A 
unifying feature of all tumors was a collagenous stroma 
with dense intercellular matrix, as highlighted by reticulin 
staining. A subset of tumors also demonstrated fibrous 
septa separating nodules of tumor cells. The background 
stroma ranged from mucin-rich, to collagenous, to nearly 
absent. Tumor cell morphology included epithelioid/rhab-
doid cells, stellate/spindle cells, and round cells (less fre-
quent). In most cases, the stellate/spindle cell morphology 
occurred in those tumors with a mucin-rich stroma, but 
occasional tumors were also seen with epithelioid mor-
phology and a mucin-rich stroma histologically mimick-
ing chordoid meningioma (Figure 5). Mitotic activity was 
generally low, typically less than 5 mitoses per 1  mm2. 
Dense lymphoplasmacytic cuffing at the tumor periphery 
or along fibrous septa and evidence of prior intratumoral 
hemorrhage with hemosiderin or hematoidin were seen in 
the majority of cases. Hemangioma-like collections of di-
lated thin-walled vessels were a frequent finding, whereas 
staghorn-like branching vessels characteristic of solitary 
fibrous tumor/hemangiopericytoma were infrequent. 
Blood-filled pseudoangiomatous spaces characteristic of 
AFH occurring in extracranial soft tissue were not ob-
served. Cellular whorls resembling those of meningioma 
were observed in a subset. Necrosis was not a common 
feature but was observed in two tumors. Most tumors 
demonstrated relatively monotonous round or ovoid 
nuclei, but two of the tumors (CREB1 #5 and FUS #1) 
demonstrated increased nuclear pleomorphism and cyto-
logic atypia. Tumor CREB1 #5 with EWSR1-CREB1 fu-
sion was predominantly composed of stellate/spindle cells 
in a mucin-rich stroma with abrupt transition to hypercel-
lular foci of cytologically atypical and mitotically active 
cells lacking a myxoid stroma. Tumor FUS #1 with FUS-
CREM fusion was composed of dense sheets of epithe-
lioid to rhabdoid cells with striking cytologic atypia and 
mitotic activity diffusely throughout the tumor (Figure 6).
When comparing histologic features versus spe-
cific fusion type, four histologic features were sig-
nificantly enriched in specific fusion types (Table 2). 
TA B L E  2  Histologic features of intracranial mesenchymal tumors with FET-CREB fusions
Histologic feature All tumors EWSR1-ATF1 EWSR1-CREB1 EWSR1-CREM FUS-CREM
Mucin-rich stromaa 12/20 (60%) 3/8 (38%) 7/7 (100%) 2/4 (50%) 0/1 (0%) p = 0.03
Collageneous stroma - intercellular 
matrix
20/20 (100%) 8/8 (100%) 7/7 (100%) 4/4(100%) 1/1 (100%)
Collagenous stroma - internodular 
septae
14/20 (70%) 4/8 (50%) 6/7 (86%) 3/4 (75%) 1/1 (100%)
Epithelioid/rhabdoid morphologya 10/20 (50%) 7/8 (88%) 1/7 (14%) 1/4 (25%) 1/1 (100%) p = 0.01
Stellate/spindle cell morphologya 10/20 (50%) 1/8 (13%) 7/7 (100%) 2/4 (50%) 0/1 (0%) p = 0.001
Round cell morphology 2/20 (10%) 1/8 (13%) 0/7 (0%) 1/4 (25%) 0/1 (0%)
Hemangioma-like vasculaturea 10/20 (50%) 2/8 (25%) 6/7 (86%) 2/4 (50%) 0/1 (0%) p = 0.04
Staghorn/HPC-like vasculature 4/20 (20%) 1/8 (13%) 1/7 (14%) 2/4 (50%) 0/1 (0%)
Pseudoangiomatoid vasculature 0/20 (0%) 0/8 (0%) 0/7 (0%) 0/4 (0%) 0/1 (0%)
Dense lymphoplasmacytic cuffing 12/20 (60%) 4/8 (50%) 6/7 (86%) 1/4 (25%) 1/1 (100%)
Hemosiderin/hematoidin 13/20 (65%) 3/8 (38%) 6/7 (86%) 3/4 (75%) 1/1 (100%)
Meningioma-like whorls 4/20 (20%) 3/8 (38%) 0/7 (0%) 1/4 (25%) 0/1 (0%)
Amianthoid fibers 2/20 (10%) 1/8 (13%) 1/7 (14%) 0/4 (0%) 0/1 (0%)
Necrosis 2/20 (10%) 1/8 (13%) 0/7 (0%) 1/4 (25%) 0/1 (0%)
aDenotes histologic features which are (bold values) statistically significantly different (p < 0.05) when comparing tumors with EWSR1-ATF1 fusion versus 
EWSR1-CREB1 fusion via unpaired, non-parametric t-test (Mann-Whitney). 
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Epithelioid or rhabdoid cell morphology was more 
often observed in tumors with EWSR1-ATF1 fusion 
versus EWSR1-CREB1 fusion (p = 0.01). Conversely, 
mucin-rich stroma, stellate/spindle cell morphology, 
and hemangioma-like vasculature were more likely 
to be observed in tumors with EWSR1-CREB1 fusion 
versus EWSR1-ATF1 fusion (p = 0.03, 0.001, and 0.04, 
respectively).
3.5 | Immunohistochemical features
All evaluated tumors in this cohort were positive for 
desmin expression, which ranged from diffuse strong 
labeling to limited focal clusters of tumor cells (Table 3 
and Figure 7). The majority of cases were also positive 
for EMA and CD99 in a membranous pattern. Variable 
S100, synaptophysin, and CD68 immunostaining was 
F I G U R E  5  Intracranial mesenchymal tumor with FET-CREB fusion can histologically mimic chordoid meningioma. Patient ATF1 #2 is a 
9-year-old female who presented with an extra-axial mass along the cerebral convexity of the left frontal lobe. Surgical resection demonstrated 
a neoplasm composed of cords and clusters of epithelioid cells in a mucin-rich stroma closely resembling chordoid meningioma. However, the 
tumor was negative for SSTR2A expression and contained small foci of tumor cells with desmin expression. Genomic interrogation revealed 
an in-frame EWSR1-ATF1 fusion and absence of mutations involving NF2 and other genes characteristic of meningioma
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also observed in a subset of tumors. Most tumors dem-
onstrated no immunoreactivity for cytokeratins AE1/AE3 
and CAM5.2, with only one tumor demonstrating focal 
labeling for AE1/AE3. MUC4 immunostaining was ob-
served in five of seven evaluated tumors, which ranged 
from diffuse strong labeling to focal clusters of positive 
F I G U R E  6  Intracranial mesenchymal tumor with FUS-CREM fusion. A, A 4-year-old girl presented with fevers and headaches and was 
found to have a large circumscribed and heterogeneously-enhancing mass in the left occipital region of the brain with significant peritumoral 
edema. After gross total resection, local tumor recurrence was seen on follow-up imaging as multiple-enhancing nodules at the periphery of 
the prior resection cavity. B, Histologic sections demonstrated a highly cellular neoplasm with both sheet-like and papillary growth patterns 
composed of epithelioid to rhabdoid tumor cells with prominent nuclear pleomorphism and atypia. C, Chromosomal copy number plot 
demonstrates that the FUS-CREM fusion was the result of an unbalanced translocation between chromosome 10p11.21 and chromosome 
16p11.2. D, Schematic of the FUS-CREM gene fusion. E, Sanger chromatogram following reverse-transcription PCR of the FUS-CREM fusion 
transcript composed of exons 1–5 of FUS linked with exons 7–8 of CREM
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cells. Pan-NTRK immunohistochemistry demonstrated 
positivity in only one of five evaluated tumors. All evalu-
ated tumors were negative for expression of glial fibrillary 
acidic protein (GFAP), myogenin, somatostatin recep-
tor 2A (SSTR2A), and HMB45. All tumors tested (n = 5) 
had intact/retained expression of INI-1 (also referred to 
BAF47 or SMARCB1). Reticulin staining demonstrated 
abundant intercellular basement membrane deposition in 
all evaluated tumors (n = 12). The Ki-67 labeling index 
was generally low (less than 5%, seven of the 13 evaluated 
tumors), but occasionally was elevated up to 15–20% (six 
of the 13 evaluated tumors). There was no significant as-
sociation of specific CREB fusion partner with distinct 
immunophenotype or Ki-67 labeling index observed.
3.6 | Clinical outcomes
The complete clinical data including extent of resec-
tion, treatment regimen, and outcome data from the 20 
patients are presented in Table 1 and Table S1. Nine 
patients initially had a gross total resection, whereas 
only a subtotal resection was achieved in eight patients. 
Extent of resection was unknown in the remaining three 
patients. None of the patients who had gross total resec-
tion were treated with adjuvant therapy, whereas five 
of the eight patients who had subtotal resection were 
treated with adjuvant radiation (n = 3), adjuvant chem-
otherapy (n = 1), or both radiation and chemotherapy 
(n = 1). The chemotherapy regimens were both sarcoma-
based using ifosfamide together with vincristine and 
doxorubicin or carboplatin and etoposide. Among the 
19 patients with available clinical follow-up, 11 patients 
(58%) experienced tumor recurrence/progression and 
three patients (16%) died of disease, all of whom had 
tumors with EWSR1-ATF1 fusion that were subtotally 
resected. Kaplan–Meier analysis of overall survival and 
progression-free survival stratified by extent of resec-
tion revealed that subtotal resection was associated with 
increased risk of death and tumor recurrence, although 
neither was statistically significant (Figure 8). Seven of 
the nine patients (78%) with subtotal resection experi-
enced local recurrence/progression within 12  months, 
and one patient (ATF1 #6) developed metastatic disease 
to the thoracic spine and lymph nodes. Kaplan–Meier 
analysis of overall survival and progression-free survival 
stratified by mucin-rich versus mucin-poor stroma re-
vealed a possible trend toward improved outcomes for 
those tumors with mucin-rich stroma, although this 
was not statistically significant (Figure 9). Among the 
12 cases with available clinical follow-up data that were 
evaluated for Ki-67 labeling index, the subset of patients 
with elevated tumor proliferative indices (greater than 
5%) had increased frequency of recurrence (five of six 
patients [83%]), whereas the subset of patients with low 
tumor proliferative indices (less than 5%) had lower fre-
quency of recurrence (three of six patients [50%]).
In order to further assess the clinical outcomes for 
these tumors, we next curated clinical data from all re-
ported cases of intracranial mesenchymal tumors with 
confirmed FET-CREB fusions published in the scien-
tific literature to date (Table 4). Patient age, sex, tumor 
location, and survival data were analyzed from the 20 
patients in our cohort together with these 18 previ-
ously reported patients (Figure 10). The median patient 










Desmin 16/16 (100%) 7/7 (100%) 6/6 (100%) 2/2 (100%) 1/1 (100%)
EMA 13/14 (93%) 5/5 (100%) 5/6 (83%) 2/2 (100%) 1/1 (100%)
CD99 10/11 (91%) 4/5 (80%) 4/4 (100%) 1/1 (100%) 1/1 (100%)
S100 5/12 (42%) 3/6 (50%) 2/5 (40%) ND 0/1 (0%)
CD68 5/6 (100%) 1/1 (100%) 2/3 (100%) 1/1 (100%) 1/1 (100%)
MUC4 5/7 (71%) 3/5 (60%) 1/1 (100%) 1/1 (100%) ND
pan-NTRK 1/5 (20%) 0/3 (0%) 1/1 (100%) 0/1 (0%) ND
Synaptophysin 5/8 (63%) 1/2 (50%) 2/4 (50%) 1/1 (100%) 1/1 (100%)
GFAP 0/9 (0%) 0/1 (0%) 0/6 (0%) 0/1 (0%) 0/1 (0%)
Myogenin 0/6 (0%) ND 0/4 (0%) 0/1 (0%) 0/1 (0%)
SSTR2a 0/8 (0%) 0/4 (0%) 0/3 (0%) ND 0/1 (0%)
HMB45 0/6 (0%) 0/3 (0%) 0/2 (0%) ND 0/1 (0%)
Cytokeratin 
AE1/AE3
1/7 (17%) 1/2 (50%) 0/4 (0%) 0/1 (0%) ND
Cytokeratin 
CAM5.2
0/9 (0%) 0/2 (0%) 0/5 (0%) 0/1 (0%) 0/1 (0%)
TA B L E  3  Immunohistochemical 
features of intracranial mesenchymal 
tumors with FET-CREB fusions
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diagnosis. These 38 patients included 12 males and 26 
females. Tumors were located at the cerebral convexi-
ties (n = 14), falx (6), lateral ventricle (6), third ventricle 
(1), skull base (1), CP angle (5), tentorium (3), and spinal 
cord (1). No significant association of fusion type with 
patient age or tumor location was apparent (Figure 10). 
F I G U R E  7  Immunohistochemical features of intracranial mesenchymal tumors with FET-CREB fusion. These tumors were uniformly 
positive for desmin expression, which ranged from diffuse strong labeling to cases with focal clusters of positive cells only. Most tumors were 
also positive for EMA and CD99 expression in a membranous distribution. A subset of tumors demonstrated positivity for synaptophysin that 
ranged from diffuse strong to more focal and weak staining. These tumors were uniformly negative for SSTR2A, GFAP, and HMB45. Most 
tumors were negative for cytokeratin expression, with only a single tumor that demonstrated focal positivity for cytokeratin AE1/AE3 (not 
shown)
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Kaplan–Meier analysis for the 38 patients revealed a 
median overall survival of greater than 60 months with 
91% survival rate at 5 years (Figure 11A), and a median 
progression-free survival of 28  months (Figure 11B). 
Kaplan–Meier analysis of overall survival or progres-
sion-free survival stratified by fusion type did not iden-
tify a statistically significant difference in outcomes 
(Figure 11C,D). However, three patients with tumors 
containing EWSR1-ATF1 fusion succumbed to disease, 
while all patients with EWSR1-CREB1 or EWSR1-
CREM fusion remained alive at time of last clinical 
follow-up.
4 |  DISCUSSION
Here, we have studied a cohort of 20 patients with in-
tracranial mesenchymal tumors harboring FET-CREB 
fusions, and comprehensively characterized their 
radiologic, molecular, and clinicopathologic features. 
Additionally, we have compiled and reviewed the 18 
previously reported cases of intracranial tumors demon-
strated to have EWSR1 or FUS fused to a CREB family 
gene. Our findings demonstrate that these tumors occur 
with a female predominance (12 males/26 females) in a 
wide age range (4–70  years old), but most often occur 
in the second and third decades of life (median age of 
17  years). They are predominantly extra-axial or in-
traventricular tumors which can arise throughout the 
neuroaxis, including the falx, tentorium, cerebral convex-
ities, skull base, spinal cord, lateral ventricle, and third 
ventricle. They are typically contrast-enhancing masses, 
well circumscribed with solid and cystic growth patterns, 
and often have pronounced peritumoral edema. Of the 38 
total tumors, 15 had EWSR1-ATF1 fusion, 13 EWSR1-
CREB1, 9 EWSR1-CREM, and 1 FUS-CREM. Beyond 
the oncogenic fusions, no additional pathogenic muta-
tions, amplifications, or deletions were identified in our 
tumor cohort by a broad NGS panel of approximately 
500 cancer-associated genes. Most of these tumors dem-
onstrated a diploid or near-diploid genome with a pau-
city of chromosomal gains and losses. While all tumors 
with EWSR1-ATF1 and EWSR1-CREB1 fusions were 
the result of balanced translocations, all tumors with 
EWSR1-CREM or FUS-CREM fusions demonstrated 
intrachromosomal copy number breakpoints occurring 
at the CREM and EWSR1 or FUS loci, indicative of un-
balanced translocation as the mechanism of gene fusion. 
The reason for this divergence in unbalanced versus bal-
anced translocations for tumors with CREM as the fusion 
partner versus those with ATF1 or CREB1 is uncertain.
Histologically, intracranial mesenchymal tumors 
with FET-CREB fusions demonstrate a range of mor-
phologic features that encompass both those previously 
described in AFH and IMMT. We note that tumors 
with CREB1 or CREM as the fusion partners are en-
riched for those with stellate/spindle cell morphology 
and prominent myxoid stroma, and those with ATF1 
are enriched for those with epithelioid morphology with 
mucin-poor stroma. However, this was not always the 
case, as we encountered tumors with EWSR1-CREB1 
fusion and epithelioid morphology with mucin-poor 
stroma, as well as tumors with EWSR1-ATF1 fusion 
and stellate/spindle cell morphology with mucin-rich 
stroma. Additionally, a subset of tumors contained 
both of these morphologic patterns within the same re-
section specimen. No immunophenotypic differences 
were noted when stratifying tumors by fusion type or 
morphologic pattern.
In terms of clinical outcomes, these tumors demon-
strate a propensity for local recurrence and occasion-
ally dissemination or metastasis leading to mortality. 
The available data suggest improved outcomes for pa-
tients that are able to undergo gross total resection. 
The growth rates have been variable, and the interval 
to disease recurrence has been up to 10 years. While 
optimal treatment strategy remains to be defined, 
F I G U R E  8  Clinical outcomes for patients with intracranial 
mesenchymal tumors with FET-CREB fusion based on extent of 
surgical resection. A, Kaplan–Meier plot of the overall survival for 
the 17 patients from this study with known extent of resection. B, 
Kaplan–Meier plot of progression-free survival for the 17 patients 
from this study with known extent of resection. Compared to gross 
total resection, subtotal resection was associated with increased risk 
of death and tumor recurrence (although neither was statistically 
significant)
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adjuvant radiation may be a consideration given the 
propensity for local recurrence, especially for incom-
pletely resected tumors. Histologic features or other 
criteria to predict disease course were not identified 
by this study, although the three patients who died of 
disease all had EWSR1-ATF1 fusions. Larger patient 
cohorts are needed to define prognostic criteria for 
these neoplasms.
These intracranial mesenchymal tumors with FET-
CREB fusion can both radiographically and histo-
logically mimic a number of other intracranial tumor 
entities. The extra-axial location and dural tail seen 
radiologically in a subset of tumors can result in a pre-
operative impression of meningioma or solitary fibrous 
tumor/hemangiopericytoma. Microscopically, these tu-
mors can feature syncytial growth and meningioma-like 
whorls that closely resemble meningioma. Additionally, 
those with rhabdoid cytology, or with cords of epithe-
lioid cells in a mucin-rich stroma, could be misinter-
preted as rhabdoid or chordoid variants of meningioma 
(Figure 4). The frequent expression of EMA in these 
tumors can further confound the differential diagnosis 
of meningioma. Fortunately, these tumors are negative 
for SSTR2A and positive for desmin, which can be 
used to distinguish them immunohistochemically. 
Furthermore, FET-CREB fusions are specific to these 
tumors and are not found in meningiomas, and all the 19 
tumors analyzed by next-generation sequencing in this 
study lacked meningioma-associated mutations in NF2, 
TRAF7, KLF4, SMO, AKT1, PIK3CA, and BAP1. The 
extra-axial location and prominent collagenous stroma 
can also raise the diagnostic possibility of solitary fi-
brous tumor/hemangiopericytoma. However, intracra-
nial mesenchymal tumors with FET-CREB fusions lack 
nuclear STAT6 immunopositivity and the characteristic 
NAB2-STAT6 fusion. They are desmin positive, but lack 
expression of skeletal muscle markers including myo-
genin and MyoD1 that allows distinction from rhabdo-
myosarcoma. They uniformly have intact expression of 
INI1 and lack SMARCB1 mutations or deletions, which 
distinguishes them from atypical teratoid/rhabdoid 
tumor and proximal-type epithelioid sarcoma. A subset 
of these tumors demonstrates MUC4 immunopositivity, 
a protein marker previously thought to be highly specific 
to low-grade fibromyxoid sarcoma and sclerosing epi-
thelioid fibrosarcoma, tumor entities which are defined 
F I G U R E  9  Clinical outcomes for patients with intracranial mesenchymal tumors with FET-CREB fusion based on mucin content of the 
stroma. A and B, Kaplan–Meier plot of overall survival (A) and progression-free survival (B) for the 20 patients from this study stratified by 
mucin-rich versus mucin-poor stroma
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by fusion of FUS (or rarely EWSR1) to either CREB3L1 
or CREB3L2. The subset of tumors with round cell 
morphology, collagenous stroma, and polyphenotypic 
differentiation by immunohistochemistry with the com-
bination of desmin, EMA, and synaptophysin positiv-
ity overlaps with desmoplastic small round cell tumor 
(DSRCT), which do rarely occur intracranially (39). 
Fluorescence in situ hybridization showing EWSR1 
break-apart does not allow distinction between DSRCT 
with EWSR1-WT1 fusions and those intracranial mes-
enchymal tumors with EWSR1 fusions to CREB family 
members. Therefore, the distinction from DSRCT re-
quires additional testing to determine the specific fusion 
partner. The possibility of a brain metastasis from a pri-
mary extracranial tumor should be considered as part 
of the workup of these patients, although all of these 
tumors described to date have appeared to be primary 
intracranial neoplasms. Noteworthy is that these intra-
cranial mesenchymal tumors with FET-CREB fusion 
are negative for expression of melanocytic markers such 
as HMB45 and MITF that is characteristic of clear cell 
sarcoma of soft tissue, and are almost always positive 
for desmin expression which is absent in both clear cell 
sarcoma of soft tissue and primary pulmonary myxoid 
sarcoma (11,13).
Because of the overlapping histologic, immunopheno-
typic, and molecular features of IMMT and intracranial 
AFH-like neoplasms, there has been ongoing uncertainty 
as to whether these tumors represent two distinct entities, 
versus a single entity defined by intracranial location and 
FET-CREB fusions (1,3). The overlapping histologic spec-
trum seen across these tumors with different fusion types 
(and even within the same tumor) suggests that intracra-
nial AFH and IMMT may likely represent morphologic 
variants of a single biologic tumor entity. In support of 
this, the clinical outcome data did not show significant 
differences in overall or progression-free survival when 
stratified by fusion type or mucin-rich versus mucin-poor 
stroma.
In summary, we have characterized a group of intra-
cranial tumors with FET-CREB fusions, which to date 
have been categorized as either intracranial AFH or 
IMMT. Further investigation including epigenetic pro-
filing is needed to define the true nature of these unique 
intracranial neoplasms and their exact relationship to 
extracranial tumors with similar fusions. Future stud-
ies are also needed to explore the relationships between 
patient outcomes and additional clinicopathologic vari-
ables such tumor location, extent of resection, fusion 
type, and morphologic features.
F I G U R E  10  Anatomic location and age at diagnosis for intracranial mesenchymal tumors with FET-CREB fusion from this study 
combined with all previously reported cases in the literature (see Table 4). A, Plot of patient age at diagnosis versus gene fusion. B, Diagram of 
tumor locations. C. Plot of tumor location versus gene fusion
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